Upon maximum tolerated dose determination , patients with low-RAS signature , high-IGF1 expression ovarian cancer were randomised to dalotuzumab/MK -2206 versus dalotuzumab/ridaforolimus , whereas patients with high IGF1/low IGF2 expression colorectal cancer received dalotuzumab/MK -0752 .